

Pediatric Complex Care **Sialorrhea Clinic Checklist**

Name:

Age:

ID:

Past Medical History

1. ***
2. ***

Medications

1. ***
2. ***

Feeding and hydration history

Feeding/fluid intake:

Voiding:

Sialorrhea

- **Type?** Anterior Posterior Both
- **Contributing factors:**
 - GERD controlled? Yes No
 - Sialorrhea increases after feeding? Yes No
 - Tooth eruption? Yes No
 - Dental carries? Yes No
 - Dental malocclusion? Yes No
 - Any medications contributing to sialorrhea? Yes No
 - Co-existing epilepsy? Yes No
 - Poor or no speech? Yes No
 - Intellectual disability? Yes No
 - Head/body positioning contributing to sialorrhea? Yes No
- **How severe?** _____
- **How frequent?** _____

Severity	Frequency
1 Dry – never drools	1 Never drools
2 Mild – only wet on the lips	2 Occasionally drools
3 Moderate – wet on the lips and chin	3 Frequently drools
4 Severe – drools to the extent that clothing becomes damp	4 Constant drooling
5 Profuse – clothing, hands, tray and objects are wet	

The drooling rankings from both scales are added together to make a combined drooling score

- **Secretions consistency?** Thin Thick Very thick
- **Complications:**
 - Skin irritation Unpleasant odour Caregiver and teacher stress Social impact
 - Damage to clothing/bibs/communication devices Interference with speech
 - Recurrent/chronic respiratory symptoms Aspiration pneumonia Frequent suctioning/injury
 - Dehydration

Management:

Current management:

(1) Non-pharmacological management:

- Use of bibs/towels/clothing (dip, not wipe) PRN
- Use of suctioning PRN (gentle) (specify): _____
- Oro-motor therapy (specify): _____
- Behavioral therapy (specify): _____
- Intra-oral appliances (specify): _____
- Adjust hydration status (specify): _____

(2) Pharmacological management:

- Atropine PO drops (specify dose): _____
- Glycopyrrolate (specify dose): _____
- Others (specify): _____

Side effects:

- Any? _____

(3) Botox injections:

- How frequent? _____
- Last injection? _____
- Effects? _____
- Side effects? _____

(4) Surgical management:

- Surgical intervention? _____
- Date? _____
- Effects? _____
- Complications? _____

Management recommendations:

(1) Non-pharmacological management:

- Optimize contributing factors (specify): _____
- Use of bibs/towels/clothing (dip, not wipe) PRN
- Use of suctioning PRN (gentle) (specify): _____
- Oro-motor therapy (specify): _____
- Behavioral therapy (specify): _____
- Intra-oral appliances (specify): _____
- Adjust hydration status (specify): _____

(2) Pharmacological management:

- Atropine PO drops (specify dose): _____
- Glycopyrrolate (specify dose): _____
- Others (specify): _____

<p><u>Contraindications:</u></p> <ul style="list-style-type: none"><input type="checkbox"/> Glaucoma<input type="checkbox"/> Tachyarrhythmias<input type="checkbox"/> Paralytic ileus/GI obstruction<input type="checkbox"/> Urinary tract obstruction (check RFT and renal U/S before use, if available)<input type="checkbox"/> Hyperthyroidism<input type="checkbox"/> Pregnancy<input type="checkbox"/> Myasthenia graves <p><u>Side effects:</u></p> <ul style="list-style-type: none"><input type="checkbox"/> Side effects reviewed
--

(3) Botox injections:

- Will make referral to ENT
- Will make referral to IR

<ul style="list-style-type: none"><input type="checkbox"/> Procedure explained<input type="checkbox"/> Timeline explained<input type="checkbox"/> Complications explained

(4) Surgical management:

- Patient will not feed orally and will make referral to ENT for: _____

<ul style="list-style-type: none"><input type="checkbox"/> Procedure explained<input type="checkbox"/> Timeline explained<input type="checkbox"/> Complications explained

Management of sialorrhea																																					
Indication	If no/minimal complications → no treatment indicated																																				
Conservative	1) Assess/correct factors that may contribute to sialorrhea: Positioning, medications, GERD, dental issues 2) Bibs (dap NOT wipe), suctioning (gentile), oro-motor therapy (by OT/SLP), behavioral therapy (by psychologist), intra-oral appliances (be dentist), optimizing TF (lower acceptable TFI)																																				
Meds	Medication MoA																																				
	Reduction of saliva production (blocks parasympathetic innervation to glands)																																				
	Medication options																																				
	<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; vertical-align: top;"> Atropine (PO drops) <ul style="list-style-type: none"> ▪ 1% ophthalmic solution (pharmacy cab make 0.25% & 0.5% solutions) ▪ DOSE: 1-2 drops given sublingually q4-6hr (can be given less frequently, i.e., OD, BID or TID) ▪ Route: Sublingual (make sure to dry mouth/suction before use) ▪ Wash hands after use (causes dilated pupils if in contact with eyes) ▪ 1% atropine covered by OHIP ▪ Inform parents that the container says "eye drops" </td> <td style="width: 50%; vertical-align: top;"> Glycopyrrolate (PO/GT/JT) <ul style="list-style-type: none"> ▪ DOSE: Initial dose 0.02 mg/Kg/DOSE TID, titrate up every 5-7 days to 0.1 mg/Kg/DOSE TID, max 3 mg TID ▪ Route: PO ▪ Does not cross BBB = less CNS toxicity and side effects ▪ May increase gastric acid secretion ▪ Specific contraindication: Glaucoma ▪ Can compound using the IV formulation ▪ Expensive/not covered by OHIP ▪ To discontinue, gradually wean over 2 weeks to prevent withdrawal symptoms </td> </tr> </table>	Atropine (PO drops) <ul style="list-style-type: none"> ▪ 1% ophthalmic solution (pharmacy cab make 0.25% & 0.5% solutions) ▪ DOSE: 1-2 drops given sublingually q4-6hr (can be given less frequently, i.e., OD, BID or TID) ▪ Route: Sublingual (make sure to dry mouth/suction before use) ▪ Wash hands after use (causes dilated pupils if in contact with eyes) ▪ 1% atropine covered by OHIP ▪ Inform parents that the container says "eye drops" 	Glycopyrrolate (PO/GT/JT) <ul style="list-style-type: none"> ▪ DOSE: Initial dose 0.02 mg/Kg/DOSE TID, titrate up every 5-7 days to 0.1 mg/Kg/DOSE TID, max 3 mg TID ▪ Route: PO ▪ Does not cross BBB = less CNS toxicity and side effects ▪ May increase gastric acid secretion ▪ Specific contraindication: Glaucoma ▪ Can compound using the IV formulation ▪ Expensive/not covered by OHIP ▪ To discontinue, gradually wean over 2 weeks to prevent withdrawal symptoms 																																		
	Atropine (PO drops) <ul style="list-style-type: none"> ▪ 1% ophthalmic solution (pharmacy cab make 0.25% & 0.5% solutions) ▪ DOSE: 1-2 drops given sublingually q4-6hr (can be given less frequently, i.e., OD, BID or TID) ▪ Route: Sublingual (make sure to dry mouth/suction before use) ▪ Wash hands after use (causes dilated pupils if in contact with eyes) ▪ 1% atropine covered by OHIP ▪ Inform parents that the container says "eye drops" 	Glycopyrrolate (PO/GT/JT) <ul style="list-style-type: none"> ▪ DOSE: Initial dose 0.02 mg/Kg/DOSE TID, titrate up every 5-7 days to 0.1 mg/Kg/DOSE TID, max 3 mg TID ▪ Route: PO ▪ Does not cross BBB = less CNS toxicity and side effects ▪ May increase gastric acid secretion ▪ Specific contraindication: Glaucoma ▪ Can compound using the IV formulation ▪ Expensive/not covered by OHIP ▪ To discontinue, gradually wean over 2 weeks to prevent withdrawal symptoms 																																			
Others: <ul style="list-style-type: none"> ▪ Trihexyphenidyl (Artane): <ul style="list-style-type: none"> ○ For children >3 Y/O ○ Treats both sialorrhea and spasticity/dystonia ○ DOSE: Initial dose 1 mg BID x7 days, titrate up every 3 days by 1-2 mg/day, if daily dose >10 mg → div TID-QID (not BID), target dose (6-40 mg/day), max daily dose (100 mg/day) ○ Taper gradually to D/C ▪ Ipratropium bromide (MDI) – not widely used in pediatrics for this indication 																																					
Side effects & contraindications																																					
<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; vertical-align: top;"> Side effects: <ol style="list-style-type: none"> 1) Constipation 2) Urinary retention 3) Tachycardia (more with atropine) 4) Hypertension 5) Vomiting 6) Behavioral changes/irritability 7) Over-drying of secretions 8) Facial flushing/impaired ability to sweat → risk of hyperthermia in hot environments 9) Sensitization 10) Seizure control 11) Mydriasis and cycloplegia 12) Sedation </td> <td style="width: 50%; vertical-align: top;"> Contraindications: <ol style="list-style-type: none"> 1) Glaucoma 2) Tachyarrhythmias 3) Paralytic ileus/GI obstruction 4) Urinary tract obstruction (check RFT and renal U/S before use, if available) 5) Hyperthyroidism 6) Pregnancy 7) Myasthenia graves </td> </tr> </table>	Side effects: <ol style="list-style-type: none"> 1) Constipation 2) Urinary retention 3) Tachycardia (more with atropine) 4) Hypertension 5) Vomiting 6) Behavioral changes/irritability 7) Over-drying of secretions 8) Facial flushing/impaired ability to sweat → risk of hyperthermia in hot environments 9) Sensitization 10) Seizure control 11) Mydriasis and cycloplegia 12) Sedation 	Contraindications: <ol style="list-style-type: none"> 1) Glaucoma 2) Tachyarrhythmias 3) Paralytic ileus/GI obstruction 4) Urinary tract obstruction (check RFT and renal U/S before use, if available) 5) Hyperthyroidism 6) Pregnancy 7) Myasthenia graves 																																			
Side effects: <ol style="list-style-type: none"> 1) Constipation 2) Urinary retention 3) Tachycardia (more with atropine) 4) Hypertension 5) Vomiting 6) Behavioral changes/irritability 7) Over-drying of secretions 8) Facial flushing/impaired ability to sweat → risk of hyperthermia in hot environments 9) Sensitization 10) Seizure control 11) Mydriasis and cycloplegia 12) Sedation 	Contraindications: <ol style="list-style-type: none"> 1) Glaucoma 2) Tachyarrhythmias 3) Paralytic ileus/GI obstruction 4) Urinary tract obstruction (check RFT and renal U/S before use, if available) 5) Hyperthyroidism 6) Pregnancy 7) Myasthenia graves 																																				
<table border="1" style="width: 100%; border-collapse: collapse; margin: 10px auto;"> <thead> <tr> <th colspan="4" style="text-align: center; background-color: #e1ecf4;">Comparative Effects of Anticholinergics</th> </tr> <tr> <th style="background-color: #e1ecf4;">Effect</th> <th style="background-color: #e1ecf4;">Atropine</th> <th style="background-color: #e1ecf4;">Scopolamine</th> <th style="background-color: #e1ecf4;">Glycopyrrolate</th> </tr> </thead> <tbody> <tr> <td style="background-color: #e1ecf4;">Heart rate</td> <td style="text-align: center; color: red;">++</td> <td style="text-align: center; color: red;">-/+</td> <td style="text-align: center; color: red;">+</td> </tr> <tr> <td style="background-color: #e1ecf4;">Mydriasis and cycloplegia</td> <td style="text-align: center; color: red;">+</td> <td style="text-align: center; color: red;">+++</td> <td style="text-align: center; color: red;">-</td> </tr> <tr> <td style="background-color: #e1ecf4;">Antisialagogue effect</td> <td style="text-align: center; color: red;">+</td> <td style="text-align: center; color: red;">+++</td> <td style="text-align: center; color: red;">++</td> </tr> <tr> <td style="background-color: #e1ecf4;">Sedative effect</td> <td style="text-align: center; color: red;">+</td> <td style="text-align: center; color: red;">+++</td> <td style="text-align: center; color: red;">-</td> </tr> <tr> <td style="background-color: #e1ecf4;">Increased gastric fluid pH</td> <td style="text-align: center; color: red;">-</td> <td style="text-align: center; color: red;">-</td> <td style="text-align: center; color: red;">-/+</td> </tr> <tr> <td style="background-color: #e1ecf4;">Central nervous system toxicity</td> <td style="text-align: center; color: red;">+</td> <td style="text-align: center; color: red;">++</td> <td style="text-align: center; color: red;">-</td> </tr> <tr> <td style="background-color: #e1ecf4;">Lower esophageal sphincter relaxation</td> <td style="text-align: center; color: red;">++</td> <td style="text-align: center; color: red;">++</td> <td style="text-align: center; color: red;">++</td> </tr> </tbody> </table>		Comparative Effects of Anticholinergics				Effect	Atropine	Scopolamine	Glycopyrrolate	Heart rate	++	-/+	+	Mydriasis and cycloplegia	+	+++	-	Antisialagogue effect	+	+++	++	Sedative effect	+	+++	-	Increased gastric fluid pH	-	-	-/+	Central nervous system toxicity	+	++	-	Lower esophageal sphincter relaxation	++	++	++
Comparative Effects of Anticholinergics																																					
Effect	Atropine	Scopolamine	Glycopyrrolate																																		
Heart rate	++	-/+	+																																		
Mydriasis and cycloplegia	+	+++	-																																		
Antisialagogue effect	+	+++	++																																		
Sedative effect	+	+++	-																																		
Increased gastric fluid pH	-	-	-/+																																		
Central nervous system toxicity	+	++	-																																		
Lower esophageal sphincter relaxation	++	++	++																																		

<p>Botox</p>	<ul style="list-style-type: none"> ▪ MOA: Reduction of saliva production ▪ Sites of injection: Inject submandibular and parotid glands ▪ Timeline: Onset in 1-3 days, peaks at 3-6 weeks, lasts for 3-6 months ▪ Done by ENT/IR, under local anesthesia/conscious sedation (rarely GA); requires U/S guidance; injects 2 submandibular glands +/- 1 parotid gland ▪ Side-effects (less side-effects with the image-guided approach): <ul style="list-style-type: none"> - Saliva thickening - Pain, swelling and hematoma at injection site - Mild dysphagia in first 2 weeks - Most significant reported problems are rare: <ul style="list-style-type: none"> A. Severe dysphagia in first 2 weeks (may require brief hospitalization and NG feeding) B. Aspiration pneumonia C. Loss of motor control of the head & neck
<p>Surgical</p>	<ul style="list-style-type: none"> ▪ Duct ligation (parotid, submandibular or both); parents must be aware that it is irreversible, and the child won't be able to feed orally after it's done ▪ Bilateral submandibular gland excision ▪ Submandibular duct relocation <p>- Done by ENT, under general anesthesia</p>